D. Ouellet

发表

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

J. Sosman, A. Ribas, P. Hwu, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

K. Flaherty, J. Sosman, I. Puzanov, 2012, The New England journal of medicine.

Improved survival with MEK inhibition in BRAF-mutated melanoma.

J. Utikal, D. Schadendorf, J. Becker, 2012, The New England journal of medicine.

How Modeling and Simulation Have Enhanced Decision Making in New Drug Development

B. Corrigan, Raymond Miller, J. Werth, 2005, Journal of Pharmacokinetics and Pharmacodynamics.

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

J. Utikal, A. Hauschild, D. Schadendorf, 2014, The New England journal of medicine.

Benefit–risk assessment: the use of clinical utility index

D. Ouellet, 2010, Expert opinion on drug safety.

Population pharmacokinetics of trabectedin in adolescent patients with cancer

S. Baruchel, J. Pérez-Ruixo, D. Ouellet, 2019, Cancer Chemotherapy and Pharmacology.

Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer

D. Ouellet, A. Periclou, R. Johnson, 2000, Cancer Chemotherapy and Pharmacology.

Exposure‐Response Analyses of the Effects of Pregabalin in Patients With Fibromyalgia Using Daily Pain Scores and Patient Global Impression of Change

Kaori Ito, B. Corrigan, D. Ouellet, 2010, Journal of clinical pharmacology.

Evaluation of the Effects of Food on the Single‐Dose Pharmacokinetics of Trametinib, a First‐in‐Class MEK Inhibitor, in Patients with Cancer

A. Tolcher, P. LoRusso, K. Papadopoulos, 2013, Journal of clinical pharmacology.

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

M. Brown, J. Infante, M. Millward, 2010 .

Population Pharmacokinetics of Piperacillin Using Scavenged Samples From Preterm Infants

M. Walsh, N. Newman, D. Ouellet, 2012, Therapeutic drug monitoring.

Population Pharmacokinetics of Metronidazole Evaluated Using Scavenged Samples from Preterm Infants

M. Walsh, N. Newman, P. Smith, 2012, Antimicrobial Agents and Chemotherapy.

Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin With Different Dosing Regimens Used in COVID‐19 Clinical Trials

S. Ahadieh, D. Ouellet, K. Sweeney, 2020, CPT: pharmacometrics & systems pharmacology.

Optimization of clinical dosing schedule to manage neutropenia: learnings from semi-mechanistic modeling simulation approach

D. Ouellet, N. Haddish-Berhane, Hong Xie, 2019, Journal of Pharmacokinetics and Pharmacodynamics.

Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation

J. Adams, D. Ouellet, R. A. Morrison, 2013, Drug Metabolism and Disposition.

Metabolism and Disposition of Oral Dabrafenib in Cancer Patients : Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation s

J. Adams, D. Ouellet, R. A. Morrison, 2013 .

A Single‐Dose Pharmacokinetic Study of Lasofoxifene in Healthy Volunteers and Subjects With Mild and Moderate Hepatic Impairment

D. Ouellet, M. Gardner, E. Randinitis, 2006, Journal of clinical pharmacology.

Pharmacokinetics of Quinapril in Children: Assessment during Substitution for Chronic Angiotensin‐Converting Enzyme Inhibitor Treatment

S. Daniels, W. Dreyer, D. Ouellet, 2003, Journal of clinical pharmacology.

Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.

D. Ouellet, M. Gardner, E. Randinitis, 2007, British journal of clinical pharmacology.

RAF Inhibitor Dabrafenib (GSK2118436) is Active in Melanoma Brain Metastases, Multiple BRAF Genotypes and Diverse Cancers

R. Kurzrock, J. Infante, M. Millward, 2014 .

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

D. Ouellet, L. D. De Zwart, J. Snoeys, 2018, Leukemia & lymphoma.

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

K. Flaherty, G. Shapiro, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Plasma Protein Binding on the Pharmacokinetics of Erdafitinib: Results of an Integrated Cross‐Study Analysis

D. Ouellet, Martha D Gonzalez, Lilian Y. Li, 2020, Journal of clinical pharmacology.

Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6

D. Ouellet, J. Jiao, J. de Jong, 2020, Pharmacology research & perspectives.

Efficacy and Safety Exposure–Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

E. Small, J. Pérez-Ruixo, D. Ouellet, 2020, Clinical Cancer Research.

Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model

M. Monshouwer, D. Ouellet, L. D. De Zwart, 2020, Clinical Pharmacokinetics.

Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects

J. Pérez-Ruixo, D. Ouellet, O. Ackaert, 2019, Clinical Pharmacokinetics.

Omeprazole: A Novel Antisecretory Agent for the Treatment of Acid-Peptic Disorders

D. Ouellet, G. Dukes, L. Hak, 1990, DICP : the annals of pharmacotherapy.

Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug–Drug Interaction Study

D. Ouellet, I. Poggesi, M. De Meulder, 2019, European Journal of Drug Metabolism and Pharmacokinetics.

Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer

J. P. Perez Ruixo, D. Ouellet, I. Poggesi, 2021, CPT: pharmacometrics & systems pharmacology.

Population Pharmacokinetics of Eltrombopag in Healthy Subjects and Patients With Chronic Idiopathic Thrombocytopenic Purpura

D. Ouellet, Daphne D Williams, E. Gibiansky, 2011, Journal of clinical pharmacology.

Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin.

D. Ouellet, M. Gardner, E. Randinitis, 2006, British journal of clinical pharmacology.

Population pharmacokinetics of gabapentin in infants and children

D. Ouellet, D. Wesche, E. Garofalo, 2001, Epilepsy Research.

Towards a Biological Understanding of ADHD and the Discovery of Novel Therapeutic Approaches

H. Soares, P. Seymour, R. Tannock, 2008 .

Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.

J. Leonard, A. Hsu, G. Granneman, 1998, British journal of clinical pharmacology.

Effect of Fluoxetine on Pharmacokinetics of Ritonavir

J. Leonard, A. Hsu, G. Granneman, 1998, Antimicrobial Agents and Chemotherapy.

Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours.

D. Ouellet, R. A. Morrison, K. Orford, 2014, British journal of clinical pharmacology.

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

M. Brown, R. Kurzrock, J. Infante, 2012, The Lancet.

Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia

D. Ouellet, P. Mudd, B. Johnson, 2013, Cancer Chemotherapy and Pharmacology.

Population PK/PD Modeling of Eltrombopag in Healthy Volunteers and Patients With Immune Thrombocytopenic Purpura and Optimization of Response‐Guided Dosing

D. Ouellet, E. Gibiansky, Jianping Zhang, 2011, Journal of clinical pharmacology.

Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study

D. Ouellet, J. Jiao, J. de Jong, 2017, Cancer Chemotherapy and Pharmacology.

Characteristics of pyrexia in BRAF V 600 E / K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I / II clinical trial

K. Flaherty, J. Sosman, J. Infante, 2015 .

Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma

N. Goeyvaerts, J. P. Perez Ruixo, D. Ouellet, 2022, Cancer Chemotherapy and Pharmacology.

Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies

J. Pérez-Ruixo, D. Ouellet, A. Dosne, 2019, Journal of clinical pharmacology.

Single‐Dose Gabapentin Pharmacokinetics and Safety in Healthy Infants and Children

D. Ouellet, E. Posvar, E. Randinitis, 2001, Journal of clinical pharmacology.

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.

K. Flaherty, J. Sosman, J. Infante, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of the drug interaction potential and single‐ and repeat‐dose pharmacokinetics of the BRAF inhibitor dabrafenib

P. LoRusso, J. Infante, D. Ouellet, 2015, Journal of clinical pharmacology.

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

R. Govindan, F. Hirsch, M. Brown, 2014, Clinical cancer research : an official journal of the American Association for Cancer Research.

Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites

P. Haney, V. Goodman, D. Ouellet, 2014, Journal of clinical pharmacology.

with combined dabrafenib and trametinib in a phase 1/2 clinical trial

K. Flaherty, J. Sosman, S. Swann, 2014 .

Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors.

Giselle Limentani, P. LoRusso, Sunil Sharma, 2013, Journal of pharmaceutical sciences.

Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation‐Positive Solid Tumors

D. Ouellet, R. A. Morrison, J. Botbyl, 2013, Journal of clinical pharmacology.

The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure

D. Ouellet, J. Jiao, J. Sukbuntherng, 2018, Cancer Chemotherapy and Pharmacology.

Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis

D. Ouellet, A. Vermeulen, Chuanpu Hu, 2023, Journal of Pharmacokinetics and Pharmacodynamics.

Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma

J. Chiu, O. Gardner, D. Ouellet, 2016, Cancer Chemotherapy and Pharmacology.

Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities

K. Venkatakrishnan, D. Mould, D. Ouellet, 2015, Clinical pharmacology and therapeutics.

Pharmacokinetic interaction between ritonavir and clarithromycin *

J. Leonard, A. Hsu, G. Granneman, 1998, Clinical pharmacology and therapeutics.

[O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10.

A. D. Rodrigues, D. Ouellet, M. Kukulka, 1996, Drug metabolism and disposition: the biological fate of chemicals.

Evaluation of the effect of lasofoxifene (LASO) on the pharmacokinetics (PK) of digoxin

D. Ouellet, M. Gardner, C. Bramson, 2005 .

Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measure.

D. Ouellet, D. Feltner, David E. Smith, 2010, Journal of pharmaceutical sciences.

MID3: Mission Impossible or Model‐Informed Drug Discovery and Development? Point‐Counterpoint Discussions on Key Challenges

Marc R Gastonguay, Daren Austin, Sandra A G Visser, 2020, Clinical pharmacology and therapeutics.

Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.

A. D. Rodrigues, D. Ouellet, Y. Yao, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review

D. Ouellet, Zhenhua Xu, A. Vermeulen, 2022, Clinical pharmacology and therapy.

Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study

D. Ouellet, J. Jiao, J. Sukbuntherng, 2017, Cancer Chemotherapy and Pharmacology.

Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1

Mark Slifstein, Marc Laruelle, Stefano Zamuner, 2011, Synapse.

Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure–QTc in patients with advanced or refractory solid tumors

J. Pérez-Ruixo, D. Ouellet, A. Dosne, 2019, Cancer Chemotherapy and Pharmacology.

Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit.

B. Corrigan, J. Werth, D. Ouellet, 2009, British Journal of Clinical Pharmacology.

Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models

Mats O. Karlsson, Maria C. Kjellsson, Brian Corrigan, 2011, Pharmaceutical Research.

First‐Time‐in‐Human Study With GSK1018921, a Selective GlyT1 Inhibitor: Relationship Between Exposure and Dizziness

D. Ouellet, T. Wang, V. Murthy, 2011, Clinical pharmacology and therapeutics.

A pseudo-reference region method applied to measurement of GlyT1 occupancy in human brain using [11C]GSK931145 and PET

Cristian Salinas, Marc Laruelle, Ana M. Catafau, 2010, NeuroImage.

Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma

D. Ouellet, B. Ribba, A. Suttle, 2015, CPT: pharmacometrics & systems pharmacology.

The Use of a Clinical Utility Index to Compare Insomnia Compounds: A Quantitative Basis for Benefit–Risk Assessment

J. Werth, D. Ouellet, D. Feltner, 2009, Clinical pharmacology and therapeutics.

Optimization of clinical dosing schedule to manage neutropenia: learnings from semi-mechanistic modeling simulation approach

D. Ouellet, N. Haddish-Berhane, Yue Guo, 2019, Journal of Pharmacokinetics and Pharmacodynamics.

Mechanism-based pharmacokinetic and pharmacodynamic modeling for bispecific antibodies: challenges and opportunities

D. Ouellet, Weirong Wang, Jingcheng Niu, 2023, Expert Review of Clinical Pharmacology.

Effect of Lasofoxifene on the Pharmacokinetics of Digoxin in Healthy Postmenopausal Women

D. Ouellet, M. Gardner, E. Randinitis, 2005, Journal of clinical pharmacology.

Comparison of Different Methods to Evaluate Population Dose–Response and Relative Potency: Importance of Interoccasion Variability

D. Potvin, D. Ouellet, R. Lalonde, 1999, Journal of Pharmacokinetics and Biopharmaceutics.

Training the next generation of pharmacometric modelers: a multisector perspective.

P. Bonate, B. Corrigan, M. Neely, 2023, Journal of pharmacokinetics and pharmacodynamics.

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

D. Ouellet, J. Snoeys, J. Jiao, 2018, Leukemia & lymphoma.

A STUDY OF THE EFFECTS OF INHIBITION OF CYP3A4 BY KETOCONAZOLE (K) AND CYP2C8 BY GEMFIBROZIL (G) ON THE PHARMACOKINETICS DABRAFENIB (D)

Infante, P. LoRusso, D. Ouellet, 2014 .